On January 22, 2026, Cathie Wood’s Ark Invest significantly expanded its exposure to Tempus AI through two of its flagship vehicles, acquiring a total of 13,532 shares valued at approximately $925,000. This purchase follows an even larger $5.85 million acquisition of Tempus AI stock by Ark Invest a day earlier. The move underscores Ark’s conviction in Tempus AI’s trajectory after the company reported an 83% year-over-year revenue increase for 2025, driven in large part by a 111% surge in diagnostics revenue. Such continued backing from a high-profile investor group may lend further credibility and liquidity to Tempus AI shares, potentially attracting additional institutional interest.

Tempus AI capped 2025 with total contract value (TCV) reaching $1.1 billion and secured over 70 data-sharing agreements with pharmaceutical partners, reinforcing its position in the precision medicine market. In the third quarter, the company achieved its first positive adjusted EBITDA, reflecting improved operational leverage despite ongoing investments in research and development. The expansion of its customer base to more than 500 oncology clinics and a doubling of its AI model deployments across hospital networks highlight accelerating adoption of Tempus’s end-to-end genomic and clinical data platform.

In late January 2026, Tempus AI unveiled Paige Predict, an AI-powered digital pathology suite capable of analyzing hematoxylin and eosin whole-slide images to predict the presence of clinically actionable biomarkers across 16 cancer types. Developed using a combined dataset covering more than 200,000 patient cases, the solution is designed to mitigate delays caused by insufficient tissue samples, guiding clinicians on the optimal sequence of confirmatory tests. Management projects Paige Predict could drive a 20% uplift in downstream testing volumes and incremental revenue contributions beginning in the second half of 2026, as hospital systems integrate the tool into their diagnostic workflows.